



[Home](#) / [Investors](#) / [News Releases](#)

Insmmed Announces Upcoming Data Presentations at Infectious Disease Week 2015

BRIDGEWATER, N.J., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today reported new nontuberculous mycobacteria (NTM) lung disease information will be presented at the Infectious Disease Week 2015 (IDWeek) meeting taking place in San Diego, California from October 7-11. IDWeek is the combined annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, HIV Medicine Association, and Pediatric Infectious Diseases Society.

Summarized below is the poster title and presentation time. Full abstracts for the meeting can be found on the IDWeek website at <http://www.idweek.org/>.

Presentation Title: Nontuberculous Mycobacteria Lung Infections: Pre-index Comorbidity and Utilization Patterns at a Large US Health Plan

Lead Author: W. Holt, MD

Poster Number: 574

Date: Thursday, October 8, 2015

Session Time: 12:30-2:00 PM PT

Session Title: TB: Nontuberculous Mycobacterial Infections

The posters will be made available on the company's website after presentation at the meeting.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company focused on the needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are no currently approved treatments for NTM in the United States or European Union (EU). In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM, as well as in cystic fibrosis patients with *Pseudomonas aeruginosa* lung infections. Insmmed's earlier-stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information visit www.insmed.com.
